Who can be involved:

WA only

  • Male or female, aged 25-60 (inclusive) years old (D-CAA) OR aged ≥18 years inclusive (sporadic CAA), at the time of informed consent
  • Has a genetic mutation causing D-CAA, or one first-degree relative with the mutation OR presymptomatic/early-stage sporadic CAA
  • No symptomatic ICH or maximum of 1 symptomatic ICH more than 1 year before study entry
  • Has an identified, reliable, study partner
  • Willingness to undergo study procedures.
  • Ability and willingness to provide written informed consent

Tracking the Natural History of Dutch-type Hereditary Cerebral Amyloid Angiopathy (TRACK D-CAA), as well as the sporadic CAA (sCAA) form, is a prospective observational cohort study with the overall aim to collect natural history data that can be used as trial run in data for future therapy trials in CAA. Cerebral amyloid angiopathy (CAA) is a small vessel disease that is highly prevalent in the elderly population. It is a common cause of intracerebral hemorrhage (ICH) and cognitive impairment. Although the large majority of CAA cases are sporadic, hereditary forms also exist, including Dutch-type hereditary CAA (D-CAA). The TRACK D-CAA provides a unique opportunity to study both presymptomatic, early clinical and later stages of CAA.

What is involved:

  • Baseline assessment and two annual follow-up assessments.
  • Participants will undergo clinical examination, neurological examination, memory testing, genetic testing, brain imaging, and provide blood and spinal fluid samples.

Additional info:

For further information about the TRACK D-CAA Study please contact Dr Samantha Gardener, Clinical Trial Coordinator at (08) 6457 0419 or email